September 13, 2012
Competition among pharmaceutical companies is heating up in the market for chronic obstructive pulmonary disease (COPD) treatments in Japan. Among long-acting bronchodilators, a main player in the drug therapy for COPD, the long-acting muscarinic antagonist (LAMA) Spiriva (tiotropium) has been...read more